Market Overview

Piper Sees "Meaningful Utility" from GW Phamaceuticals CBD, Reiterates Overweight Rating

Share:
Related GWPH
Pot Stock Watch: Why Is Zynerba Viewed As A Sympathy Play With GW Pharma?
Exclusive: GW Pharmaceuticals Talks Epidiolex, Raising Capital & Growing Its Sales Force
Latest GW Pharmaceuticals Cannabinoid Drug Test Results Boost Stock Price Again (Seeking Alpha)

In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH) and raised the price target from $77.00 to $97.00.

Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism.

The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the 'views from the field' represent a true drug effect.”

GW Pharmaceuticals closed at $57.71 on Thursday. Shares have traded as high as $64.73, up 12.16% on Friday. This has been the biggest intraday gain since January 9.

Latest Ratings for GWPH

DateFirmActionFromTo
Sep 2016Morgan StanleyMaintainsOverweight
Sep 2016Cantor FitzgeraldMaintainsBuy
Jun 2016Janney CapitalInitiates Coverage onSell

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Joshua Schimmer Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!